Glenn Batchelder joined the Board of Directors of The Michael J. Fox Foundation in 2015. He is a serial life science company start-up entrepreneur.
He currently serves as executive chairman for three early stage biotech companies: XyloCor Therapeutics, Synchronicity Pharma and Kantum Bio. He also serves on the Board of Directors of Synspira.
Mr. Batchelder's most recent operational role was as co-founder and CEO of Civitas Therapeutics, a company developing a therapy for treating "off" episodes associated with Parkinson's disease. Civitas was acquired by Acorda Therapeutics in October 2014. Prior to Civitas, he was the founding CEO of BIND Therapeutics, a leading nanotherapeutics company, ultimately sold to Pfizer. He was also the CEO of Acceleron Pharma, a biotherapeutics company focused on blood diseases and neuromuscular disorders. He started his biotechnology career at Millennium Pharmaceutical where he played an integral leadership role in the launch of Velcade, a breakthrough therapy for multiple myeloma.
Mr. Batchelder is passionate about translating the enormous advances in biological science and medical research of the past decade into improvements in patients' lives. He previously served as the chairman of the Board for MassBio, a nonprofit supporting the life sciences industry and eco-system in Massachusetts. Mr. Batchelder received a BS in Chemical Engineering from Lehigh University.